Brief: ABVC Biopharma provides Vitargus® update
18/08/2022 13:33
Aug 18 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA PROVIDES VITARGUS® UPDATE
* ABVC BIOPHARMA INC - PHASE II VITARGUS® CLINICAL TRIAL
RECEIVES
LOCAL ETHICS COMMITTEE APPROVAL IN THAILAND
* ABVC BIOPHARMA - IN PARALLEL, VITARGUS PHASE II STUDY
PROTOCOL
DOCUMENTS HAVE BEEN SUBMITTED TO AUSTRALIAN BELLBERRY HUMAN
RESEARCH ETHICS COMMITTEE
* ABVC BIOPHARMA - BOTH HOSPITALS NOW EXPECT TO RECEIVE A
THAI FDA
INVESTIGATIONAL PRODUCT (IP) IMPORT LICENSE WITHIN NEXT 30 DAYS
* ABVC - UPON APPROVAL BY HREC, CO WILL SUBMIT APPLICATION
TO
AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION (TGA) FOR CLINICAL
TRIAL NOTIFICATION OF STUDY
* ABVC BIOPHARMA INC - EXPECT TO BEGIN CLINICAL TRIALS IN
OTHER
ASIA-PACIFIC COUNTRIES BEFORE END OF 2022 FOR VITARGUS
Source text for Eikon: ID:nGNXXTl24
Further company coverage: ABVC.O
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner